DUEXIS (famotidine; ibuprofen) by Amgen is histamine-2 (h2) receptors. First approved in 2011.
Drug data last refreshed 9h ago · AI intelligence enriched 5d ago
DUEXIS is a fixed-dose oral combination tablet containing famotidine (an H2-receptor antagonist) and ibuprofen (an NSAID), designed to reduce gastric acid secretion while providing anti-inflammatory pain relief. It is indicated for patients requiring NSAID therapy who are at risk of NSAID-induced gastric ulcers. Famotidine inhibits gastric acid production by blocking histamine-2 receptors, protecting the stomach lining from NSAID-induced damage.
With only ~5,500 annual Part D claims and LOE arriving in mid-2026, this product is a declining niche brand requiring defensive commercial strategy and minimal team expansion.
histamine-2 (H2) receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Worked on DUEXIS at Amgen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
DUEXIS offers limited career advancement opportunities given its minimal market presence (5,500 Part D claims, $14M annual spending) and immediate loss-of-exclusivity status. This is a defensive, wind-down assignment suitable for early-career professionals seeking GI category experience or cost management specialists preparing for transition planning.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo